Updating results

6 results for amyloidosis Sort: Relevance | Date

Patisiran for treating hereditary transthyretin-related amyloidosis [ID1279]

In development [GID-HST10014] Expected publication date: TBC

Highly specialised technologies guidance In development

Inotersen for treating hereditary transthyretin-related amyloidosis [ID1242]

In development [GID-HST10013] Expected publication date: TBC

Highly specialised technologies guidance In development

Appeal panel membership

Ashutosh Wechalekar MD, FRCP, FRCPath, DM, NHS representative UK National Amyloidosis Centre, Department of Medicine, University College...

Published December 2018

Block scoping reports

treating hereditary transthyretin-related amyloidosis. Patisiran for treating hereditary transthyretin-related amyloidosis....

Published June 2018

Myeloma: diagnosis and management (NG35)

Evidence-based recommendations on the diagnosing and managing of myeloma in people aged 16 and over.

NICE guideline Published February 2016 Last updated October 2018

ESNM36: Systemic juvenile idiopathic arthritis: canakinumab

Summary of the evidence on canakinumab for treating systemic juvenile idiopathic arthritis (JIA) to inform local NHS planning and decision-making

Evidence summary Published March 2014